Improving Durability of Responses Is a Key Next Step for CAR T-cell Therapy in Myeloma

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Related Keywords

Susan Bal ,Bristol Myers Squibb ,University Of Alabama At Birmingham ,Oneal Comprehensive Cancer Center ,Drug Administration ,Medical Oncology ,O Neal Comprehensive Cancer Center ,Myers Squibb ,Idecabtagene Vicleucel ,Ciltacabtagene Autoleucel ,Patients With Relapsed Refractory Multiple Myeloma ,D ,The University Of Alabama At Birmingham ,Uab Health ,